Int J Mol Med 41: [Related article:] 679-686, 2018; DOI:
10.3892/ijmm.2017.3271
Following the publication of the above article, an
interested reader drew to the authors' and the Editor's attention
that, given the subject matter of the article, in a few places in
the text throughout the paper, 'MIR159' was probably intended to
have been written as 'MIR596', and 'miR-159' was probably meant to
have been written as 'miR-596'.
The authors have responded to confirm that the
interested reader was correct in their assessment; this paper
discusses the role of miR-596 in the context of acute myeloid
leukemia (AML) and its potential as a biomarker, and this error
appears to have occurred during the final stages of manuscript
preparation. Therefore, the following corrections to the text of
this article should be noted:
In the final sentence of the Abstract on p. 679,
'miR-596' should have been written, rather than 'miR-159'. The
corrected sentence should read as follows: 'Furthermore, the
aberrantly hypermethylated miR-596-encoding gene
MIR596 may be a potential biomarker of AML.'
In the Discussion, all instances where 'miR-159' and
'MIR159' were mentioned should be corrected to 'miR-596' and
'MIR596', respectively. The sentences concerned should have read as
follows (p. 685, right-hand column, line 9): 'Thus, it was
suggested that the hypermethylation of miR-596 may be
associated with its transcriptional regulation. It was also
inferred that miR-596 methylation in BM-MSCs may be a
biomarker or prognostic factor for patients with AML. However, the
significance of the methylation of miR-596 demands further
investigation." In addition, the sentence starting on p. 685,
right-hand column, second paragraph, line 5, should have read as
follows: 'Furthermore, the aberrant hypermethylated
miR-596-encoding gene MIR596 may be a
potential biomarker of AML.'
All the authors agree with the publication of this
corrigendum; furthermore, they also apologize to the readership of
the journal for any inconvenience caused.
